Fresenius SE & Co KGaA (FRE) Given a €78.00 Price Target at Commerzbank

Share on StockTwits

Commerzbank set a €78.00 ($90.70) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research note released on Friday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Sanford C. Bernstein set a €83.00 ($96.51) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, September 21st. Barclays set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, August 24th. Morgan Stanley set a €77.00 ($89.53) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Monday, September 3rd. Warburg Research set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Friday, September 28th. Finally, Independent Research set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of €68.69 ($79.88).

Shares of FRA FRE traded down €8.39 ($9.76) during midday trading on Friday, hitting €38.99 ($45.34). 12,548,201 shares of the company’s stock traded hands. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Hedge Funds Explained

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.